Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review

Expert Opinion on Investigational Drugs
Paula MosińskaJakub Fichna

Abstract

Constipation-predominant irritable bowel syndrome (IBS-C) is a functional gastrointestinal (GI) disorder with an unknown etiology. A number of the drugs tested for IBS-C have also been applied to chronic constipation and chronic idiopathic constipation. Unfortunately, due to severe adverse effects, many drugs envisioned for IBS-C had been withdrawn from the market. Nevertheless, a number of potential new agents for this indication are now under development. The following review describes the most recently developed agents in preclinical as well as Phase 1 and Phase 2 clinical studies. Information was obtained from published literature, abstracts and the latest results found in Clinicaltrial.gov database. The authors put a special interest on glucagon-like peptide 1 analogue, bile acid modulators, serotonergic agents, guanylate cyclase C and cannabinoid antagonists. To enter the market, a newly-developed drug has to meet several criteria, such as good bioavailability or the absence of drug-related adverse events. Taking into account constipation and abdominal pain as the main symptoms in IBS-C, a novel successful drug is usually able to improve both at the same time. Four out of fifteen investigational drugs described in this pa...Continue Reading

References

Dec 26, 2002·Japanese Journal of Pharmacology·Atsuko InuiTsugutaka Ito
Nov 18, 2003·Alimentary Pharmacology & Therapeutics·N S ColemanR C Spiller
Feb 19, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Zhi LiuTakamichi Hattori
Feb 1, 2006·PharmacoEconomics·Stefanie Maxion-BergemannRito Bergemann
May 9, 2006·Gastroenterology·George F LongstrethRobin C Spiller
Dec 13, 2006·Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi·Yu KojimaMiyako Takaki
Dec 26, 2006·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M CamilleriP Druzgala
Feb 27, 2008·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·P M HellströmS Efendic
Apr 15, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·D T BeattieP P A Humphrey
Apr 17, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·J A M SmithP P A Humphrey
May 3, 2008·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·H S KimJ L Conklin
Jun 27, 2008·Yonsei Medical Journal·Hyun Chul LimHyojin Park
Aug 2, 2008·Current Opinion in Pharmacology·Robin Spiller
Nov 6, 2009·Diabetes Research and Clinical Practice·Naohiko UenoYoshiko Satoh
Feb 2, 2010·Pharmacology & Therapeutics·Angelo A Izzo, Keith A Sharkey
Apr 23, 2010·Expert Opinion on Investigational Drugs·Noriaki ManabeMichael Camilleri
Aug 10, 2010·Current Gastroenterology Reports·Noriaki ManabeMichael Camilleri
Nov 26, 2010·Current Opinion in Gastroenterology·Kris A Steinbrecher, Mitchell B Cohen
Dec 16, 2010·Alimentary Pharmacology & Therapeutics·S Raja, A C Ford
Feb 22, 2011·Gastroenterology Clinics of North America·Monthira ManeerattanapornWilliam D Chey
Mar 31, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·S Scott BowersoxPascal Druzgala
Jun 10, 2011·Expert Review of Gastroenterology & Hepatology·Maria Vazquez Roque, Michael Camilleri
Sep 29, 2011·CNS Neuroscience & Therapeutics·Pradeep J NathanEdward T Bullmore
Apr 21, 2012·American Journal of Physiology. Gastrointestinal and Liver Physiology·Michael CamilleriAlan R Zinsmeister
May 23, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Banny S WongAlan R Zinsmeister
Jul 12, 2012·Frontiers in Pharmacology·Jakub Fichna, Martin A Storr
Dec 12, 2012·Expert Opinion on Investigational Drugs·Banny S Wong, Michael Camilleri
May 4, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Andrea ShinAlan R Zinsmeister

❮ Previous
Next ❯

Citations

Feb 27, 2017·Journal of Neurogastroenterology and Motility·Paula MosińskaJakub Fichna
May 30, 2017·Journal of Neurogastroenterology and Motility·Adam FabisiakJakub Fichna
Jun 30, 2018·Expert Review of Clinical Pharmacology·Anna ZielińskaJakub Fichna
Oct 16, 2016·American Journal of Physiology. Gastrointestinal and Liver Physiology·Dervla O'Malley
Jul 17, 2019·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Maria M BuckleyDervla O'Malley
Nov 15, 2019·Expert Opinion on Pharmacotherapy·Karolina NiewinnaJakub Fichna
Oct 12, 2019·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Rebecca O'Brien, Dervla O'Malley
May 5, 2021·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Rebecca O'BrienDervla O'Malley

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.